 REDWOOD CITY, Calif., June 17, 2021 GLOBE NEWSWIRE -- Codexis, Inc. Nasdaq: CDXS, a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to 13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company. The majority of this order was not included in Codexis prior guidance for 2021; accordingly, the Company is raising its 2021 guidance for total revenues to a range of 89 million to 93 million, up from previous guidance of 82 million to 85 million. Codexis is also increasing its 2021 guidance for product revenue to a range of 45 million to 48 million, up from previous guidance of 36 million to 39 million. In addition, the Company is raising 2021 guidance for product gross margin to a range of 60 to 64, up from previous guidance of 54 to 58. 